Product Description
Desonide is used to treat the redness, swelling, itching, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Desonide is in a class of medications called topical corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching. (Sourced from: https://medlineplus.gov/druginfo/meds/a605025.html)
Mechanisms of Action: Corticosteroid Hormone Receptor Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Bangladesh | Brazil | Bulgaria | Canada | Chile | Colombia | Dominican Republic | Ecuador | Egypt | Finland | France | Hong Kong | India | Indonesia | Ireland | Italy | Korea | Lebanon | Malaysia | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Singapore | South Africa | Sri Lanka | Sweden | Tunisia | Turkey | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Minsheng Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Dermatitis|Inflammation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20212217 | P1 |
Not yet recruiting |
Dermatitis|Inflammation |
None |
|
| CTR20210696 | P1 |
Not yet recruiting |
Inflammation|Dermatitis |
None |